Semliki Forest virus-mediated gene therapy of the RG2 rat glioma

Neuropathology and Applied Neurobiology

Volumn 36, Issue 7, 2010, Pages 648-660

  Roche, F P ^a   Sheahan, B J ^b   O'Mara, S M ^a   Atkins, G J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cytokine therapy; Glioma; IL 12; RG2; Semliki Forest virus; Viral oncolysis

Indexed keywords

INTERLEUKIN 12; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EDEMA; BRAIN NECROSIS; CANNULATION; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE COMPARISON; GENE DELIVERY SYSTEM; GENE THERAPY; GLIOMA; INFLAMMATION; INOCULATION; MALE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEMLIKI FOREST ALPHAVIRUS; SURVIVAL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; VIRUS LIKE AGENT; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENDPOINT DETERMINATION; GENE THERAPY; GLIOMA; INTERLEUKIN-12; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; SEMLIKI FOREST VIRUS; STEREOTAXIC TECHNIQUES; VIRUS REPLICATION;

EID: 78349244864     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2010.01110.x     Document Type: Article

References (36)

1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22
2. Parney IF, Chang LJ. Cancer immunogene therapy: a review. J Biomed Sci 2003; 10: 37-43
3. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 2007; 18: 183-94
4. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998; 17: 269-78
5. Portielje JE, Gratama JW, Van Ojik HH, Stoter G, Kruit WH. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 2003; 52: 133-44
6. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697-706
7. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165: 2665-70
8. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-6
9. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457-64
10. Chen B, Timiryasova TM, Haghighat P, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 2001; 24: 46-57
11. Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 2005; 12: 1253-63
12. Iwashita Y, Ogawa T, Goto S, Nakanishi M, Goto T, Kitano S. Effective transfer of interleukin-12 gene to solid tumors using a novel gene delivery system, poly [D, L-2, 4-diaminobutyric acid]. Cancer Gene Ther 2004; 11: 103-8
13. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97: 2208-13
14. Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villarreal LP, Black KL, Yu JS. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002; 9: 9-15
15. Minuzzo S, Moserle L, Indraccolo S, Amadori A. Angiogenesis meets immunology: cytokine gene therapy of cancer. Mol Aspects Med 2007; 28: 59-86
16. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40
17. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994; 58: 491-562
18. Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 1991; 9: 1356-61
19. Smerdou C, Liljestrom P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 1999; 73: 1092-8
20. Ventoso I, Sanz MA, Molina S, Berlanga JJ, Carrasco L, Esteban M. Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev 2006; 20: 87-100
21. Glasgow GM, McGee MM, Tarbatt CJ, Mooney DA, Sheahan BJ, Atkins GJ. The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol 1998; 79: 2405-10
22. Murphy FJ, Hayes MP, Burd PR. Disparate intracellular processing of human IL-12 preprotein subunits: atypical processing of the P35 signal peptide. J Immunol 2000; 164: 839-47
23. Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther 2005; 12: 147-59
24. Chikkanna-Gowda CP, McNally S, Sheahan BJ, Fleeton MN, Atkins GJ. Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18. Oncol Rep 2006; 16: 713-19
25. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998; 36: 91-102
26. Tzeng JJ, Barth RF, Orosz CG, James SM. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 1991; 51: 2373-8
27. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997; 32: 253-65
28. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-7
29. Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005; 12: 153-63
30. Yamanaka R, Zullo SA, Tanaka R, Ramsey J, Blaese M, Xanthopoulos KG. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus 2000; 9: e7
31. Seitz RJ, Deckert M, Wechsler W. Vascularization of syngenic intracerebral RG2 and F98 rat transplantation tumors. A histochemical and morphometric study by use of ricinus communis agglutinin I. Acta Neuropathol 1988; 76: 599-605
32. Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, Barbier EL. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 2008; 21: 1043-56
33. Maatta AM, Liimatainen T, Wahlfors T, Wirth T, Vaha-Koskela M, Jansson L, Valonen P, Hakkinen K, Rautsi O, Pellinen R, Makinen K, Hakumaki J, Hinkkanen A, Wahlfors J. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer 2007; 121: 863-70
34. Rodriguez-Madoz JR, Prieto J, Smerdou C. Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration. Mol Ther 2007; 15: 2164-71
35. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995; 55: 1902-10
36. Graham A, Walker R, Baird P, Hahn CN, Fazakerley JK. CNS gene therapy applications of the Semliki Forest virus 1 vector are limited by neurotoxicity. Mol Ther 2006; 13: 631-5